MK-1045 not checked

Merck & Co. · CN201

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
8 active
8 in total · 5 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“MK-1045 is administered by IV infusion once a week (QW), 4 weeks per treatment cycle, starting with 2 cycles of induction treatment. After a 2-week treatment-free interval, responders to induction treatment receive 3 cycles of consolidation therapy, and up to 7 cycles of maintenance treatment or until intolerable toxicity, disease progression, withdrawal of informed consent, loss to follow-up,…”In the company’s words, NCT05579132 on ClinicalTrials.gov
Tested for
Lymphoma, Large B-Cell, Diffuse (2 trials), Follicular Lymphoma, B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Hematologic Malignancies, Acute Lymphoblastic Leukemia and 5 more
Main trialPhase 2/3
“Researchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine called MK-1045 and rituximab can treat FL. MK-1045 is a type of treatment called immunotherapy. The goals of this study are to learn: * About the safety of MK-1045 and rituximab, and if people tolerate them when given together * If people who receive MK-1045 and rituximab have the cancer go away * If people who receive MK-1045 and rituximab live longer…”In the company’s words, NCT07634471 on ClinicalTrials.gov
Other names
CN201
Given with
Avtozma (Celltrion Inc), Tyenne (Fresenius Kabi USA)Other companies’ drugs in its trials

Other drugs for Lymphoma, Large B-Cell, Diffuse

All 86 drugs for Lymphoma, Large B-Cell, Diffuse

Coming up8

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials8

TrialPhaseCompletesWhat it tests
Phase 2/3Recruiting 23 Jul 2032 A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
Phase 2/3Recruiting 18 Oct 2033 A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Phase 2/3Not yet recruiting 13 Mar 2037 A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)
Phase 2Recruiting 16 Nov 2033 A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)
Phase 1/2Recruiting 31 Dec 2028 A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
Phase 1/2Recruiting 1 Jul 2030 A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Phase 1Recruiting 30 Sep 2028 A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)
Phase 1Recruiting 16 Jul 2029 A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow MK-1045

Following is part of Solo: you see every change to MK-1045 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in